Medpace (MEDP) to Release Earnings on Monday

Medpace (NASDAQ:MEDP) will likely be releasing its Q4 2025 results after the market closes on Monday, February 9th. Analysts expect the company to announce earnings of $4.18 per share and revenue of $689.5330 million for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, February 10, 2026 at 9:00 AM ET.

Medpace Stock Up 0.1%

Shares of Medpace stock opened at $542.04 on Friday. Medpace has a 12-month low of $250.05 and a 12-month high of $628.92. The stock has a 50 day moving average price of $579.45 and a two-hundred day moving average price of $537.91. The stock has a market capitalization of $15.27 billion, a P/E ratio of 37.90, a PEG ratio of 1.82 and a beta of 1.42.

Insider Activity

In other news, CEO August J. Troendle sold 59,025 shares of the company’s stock in a transaction dated Monday, November 24th. The shares were sold at an average price of $607.78, for a total transaction of $35,874,214.50. Following the completion of the transaction, the chief executive officer owned 774,602 shares of the company’s stock, valued at approximately $470,787,603.56. This represents a 7.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Susan E. Burwig sold 20,000 shares of Medpace stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $609.15, for a total value of $12,183,000.00. Following the sale, the vice president directly owned 27,500 shares in the company, valued at approximately $16,751,625. This trade represents a 42.11% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 320,192 shares of company stock worth $192,909,762. Insiders own 20.30% of the company’s stock.

Institutional Trading of Medpace

A number of institutional investors and hedge funds have recently modified their holdings of the company. AQR Capital Management LLC lifted its holdings in Medpace by 65.1% during the 3rd quarter. AQR Capital Management LLC now owns 1,025,410 shares of the company’s stock valued at $518,170,000 after purchasing an additional 404,226 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Medpace by 205.8% during the third quarter. Arrowstreet Capital Limited Partnership now owns 314,150 shares of the company’s stock worth $161,523,000 after buying an additional 211,411 shares in the last quarter. Wasatch Advisors LP raised its stake in shares of Medpace by 14.0% in the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock valued at $296,853,000 after acquiring an additional 116,354 shares during the last quarter. Invesco Ltd. boosted its holdings in shares of Medpace by 18.9% in the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock worth $276,313,000 after acquiring an additional 85,517 shares in the last quarter. Finally, Qube Research & Technologies Ltd grew its position in Medpace by 1,527.8% during the 3rd quarter. Qube Research & Technologies Ltd now owns 74,780 shares of the company’s stock worth $38,449,000 after acquiring an additional 70,186 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on MEDP. Weiss Ratings restated a “buy (b)” rating on shares of Medpace in a research note on Wednesday, January 28th. TD Cowen reissued a “sell” rating on shares of Medpace in a research report on Friday, October 24th. Barclays upped their price target on shares of Medpace from $485.00 to $525.00 and gave the company an “underweight” rating in a report on Monday, December 15th. Truist Financial set a $555.00 price objective on Medpace in a research note on Monday, October 27th. Finally, BMO Capital Markets initiated coverage on Medpace in a research report on Thursday, November 13th. They set a “market perform” rating and a $600.00 price objective for the company. Two research analysts have rated the stock with a Buy rating, nine have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, Medpace currently has an average rating of “Reduce” and an average target price of $491.27.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.